Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 8/20 | 0.33 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.32 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.32 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.31 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.31 |
| ▸ | HTR7 | P34969 | 2/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.30 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.30 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.30 |
| ▸ | ELANE | P08246 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31068127 | 0.91 | DDB1 (0.41) | MCHR1DDB1CRBN | |
| SCHEMBL29348462 | 0.83 | ELANE (0.33) | MCHR1ROCK2ROCK1NPC1RAB9A | |
| SCHEMBL29348402 | 0.80 | CRBN (0.38) | DDB1CRBN | |
| SCHEMBL29348470 | 0.80 | DDB1 (0.42) | DDB1CRBN | |
| SCHEMBL29348798 | 0.80 | DDB1 (0.42) | DDB1CRBN | |
| SCHEMBL29348463 | 0.79 | DDB1 (0.38) | DDB1CRBN | |
| SCHEMBL29348452 | 0.77 | DDB1 (0.44) | DDB1CRBN | |
| SCHEMBL29348202 | 0.76 | DDB1 (0.45) | DDB1CRBN | |
| SCHEMBL29348198 | 0.76 | DDB1 (0.45) | DDB1CRBN | |
| SCHEMBL29348199 | 0.76 | DDB1 (0.45) | DDB1CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024151547-A1 | TARGETED DEGRADATION OF VAV1 | MONTE ROSA THERAPEUTICS, INC. (US) | 2024-07-18 | — | — | WO | disclosed |